Survodutide

Overview

• [educational] A GLP-1 + glucagon dual agonist (metabolic/weight). — Huberman

Mechanisms

Evidence

• [literature] First Phase 3 obesity readout — SYNCHRONIZE-1 (ADA 2026; NEJM + Nature Medicine): 76-wk, 725 adults without T2D, up to 16.6% weight loss (≈17.8 kg) vs 3.2% placebo; MRI substudy fat-driven (visceral fat ↓34%, liver fat ↓up to 63%). Companion SYNCHRONIZE-MASLD supports liver-fat + weight reduction. Places survodutide in the dual-agonist tier below tirzepatide/retatrutide, with a standout liver/visceral-fat (glucagon-arm) signal. Not FDA-approved. — SOURCE-survodutide-synchronize1-phase3-2026

Anecdotes

Physician protocols

Practical notes